| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Carcinoma, Non-Small-Cell Lung | 26 | 2009 | 1131 | 1.150 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 26 | 2019 | 2506 | 1.070 |
Why?
|
| Lung Neoplasms | 28 | 2009 | 2370 | 0.960 |
Why?
|
| Esophageal Neoplasms | 7 | 2010 | 332 | 0.650 |
Why?
|
| Paclitaxel | 14 | 2008 | 474 | 0.500 |
Why?
|
| Taxoids | 7 | 2010 | 124 | 0.400 |
Why?
|
| Sulfonamides | 2 | 2008 | 319 | 0.320 |
Why?
|
| Antineoplastic Agents, Phytogenic | 6 | 2008 | 274 | 0.310 |
Why?
|
| Leukemia, Lymphoid | 11 | 1987 | 72 | 0.300 |
Why?
|
| Carcinoma, Squamous Cell | 4 | 2010 | 1098 | 0.290 |
Why?
|
| Stomach Neoplasms | 2 | 2010 | 288 | 0.270 |
Why?
|
| Survival Rate | 12 | 2019 | 1899 | 0.270 |
Why?
|
| Antineoplastic Agents | 15 | 2008 | 2331 | 0.270 |
Why?
|
| Combined Modality Therapy | 13 | 2010 | 1704 | 0.260 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2007 | 125 | 0.260 |
Why?
|
| Interprofessional Relations | 1 | 2007 | 121 | 0.260 |
Why?
|
| Carboplatin | 8 | 2008 | 312 | 0.250 |
Why?
|
| Quinazolines | 4 | 2008 | 212 | 0.240 |
Why?
|
| Neoplasms | 9 | 2007 | 3065 | 0.240 |
Why?
|
| Clinical Trials as Topic | 5 | 2007 | 1134 | 0.240 |
Why?
|
| Aged | 33 | 2019 | 19254 | 0.220 |
Why?
|
| Antimetabolites, Antineoplastic | 2 | 2019 | 233 | 0.220 |
Why?
|
| Adenocarcinoma | 3 | 2010 | 1185 | 0.210 |
Why?
|
| Aged, 80 and over | 15 | 2019 | 6783 | 0.200 |
Why?
|
| Bone Marrow | 8 | 1998 | 443 | 0.200 |
Why?
|
| Biomedical Research | 1 | 2007 | 405 | 0.200 |
Why?
|
| Neoplasm Staging | 11 | 2010 | 2000 | 0.200 |
Why?
|
| Leukemia | 6 | 1982 | 322 | 0.190 |
Why?
|
| Adult | 35 | 2010 | 26822 | 0.190 |
Why?
|
| Drug Administration Schedule | 10 | 2009 | 865 | 0.180 |
Why?
|
| Middle Aged | 33 | 2010 | 26148 | 0.180 |
Why?
|
| Capecitabine | 2 | 2019 | 93 | 0.180 |
Why?
|
| Fluorouracil | 4 | 2019 | 549 | 0.180 |
Why?
|
| Organoplatinum Compounds | 4 | 2005 | 94 | 0.180 |
Why?
|
| Camptothecin | 3 | 2008 | 195 | 0.170 |
Why?
|
| Dose-Response Relationship, Drug | 8 | 2008 | 1929 | 0.170 |
Why?
|
| Male | 46 | 2016 | 42682 | 0.170 |
Why?
|
| Humans | 75 | 2019 | 89970 | 0.170 |
Why?
|
| Female | 47 | 2019 | 46595 | 0.160 |
Why?
|
| Disease-Free Survival | 7 | 2019 | 1169 | 0.160 |
Why?
|
| Carcinoma, Small Cell | 3 | 2002 | 133 | 0.150 |
Why?
|
| Etoposide | 3 | 2008 | 206 | 0.150 |
Why?
|
| Neutrophils | 3 | 2016 | 311 | 0.150 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 2 | 1993 | 399 | 0.140 |
Why?
|
| Vascular Remodeling | 1 | 2016 | 22 | 0.140 |
Why?
|
| Mast Cells | 1 | 2016 | 94 | 0.130 |
Why?
|
| Mechanotransduction, Cellular | 1 | 2016 | 81 | 0.130 |
Why?
|
| Neovascularization, Physiologic | 1 | 2016 | 143 | 0.130 |
Why?
|
| Survival Analysis | 6 | 2009 | 1498 | 0.120 |
Why?
|
| Methotrexate | 9 | 2019 | 243 | 0.120 |
Why?
|
| Cyclophosphamide | 8 | 2019 | 301 | 0.120 |
Why?
|
| Leucovorin | 2 | 2005 | 222 | 0.120 |
Why?
|
| Breast Neoplasms | 3 | 2019 | 3022 | 0.120 |
Why?
|
| Medical Oncology | 1 | 1998 | 384 | 0.120 |
Why?
|
| Doxorubicin | 7 | 2019 | 293 | 0.120 |
Why?
|
| Disease Progression | 6 | 2009 | 1469 | 0.110 |
Why?
|
| Maximum Tolerated Dose | 4 | 2008 | 263 | 0.110 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2008 | 586 | 0.110 |
Why?
|
| Treatment Outcome | 11 | 2019 | 8273 | 0.110 |
Why?
|
| Endothelial Cells | 1 | 2016 | 464 | 0.110 |
Why?
|
| Mitosis | 9 | 1978 | 152 | 0.100 |
Why?
|
| Agranulocytosis | 3 | 1984 | 20 | 0.090 |
Why?
|
| Infusions, Intravenous | 4 | 2005 | 416 | 0.090 |
Why?
|
| Deoxycytidine | 2 | 2009 | 211 | 0.090 |
Why?
|
| Hydroxyurea | 2 | 2008 | 239 | 0.090 |
Why?
|
| Brain Neoplasms | 4 | 2006 | 784 | 0.090 |
Why?
|
| Head and Neck Neoplasms | 3 | 2007 | 1061 | 0.090 |
Why?
|
| Neoplasm Metastasis | 6 | 2009 | 1066 | 0.090 |
Why?
|
| Child | 20 | 1998 | 7244 | 0.080 |
Why?
|
| Lymphoma | 3 | 1982 | 266 | 0.080 |
Why?
|
| Ifosfamide | 4 | 2003 | 48 | 0.080 |
Why?
|
| Prognosis | 11 | 2008 | 3798 | 0.080 |
Why?
|
| Cisplatin | 5 | 2010 | 598 | 0.080 |
Why?
|
| Cell Division | 4 | 1976 | 692 | 0.080 |
Why?
|
| Neoplasm Recurrence, Local | 5 | 2009 | 1352 | 0.080 |
Why?
|
| Child, Preschool | 14 | 1998 | 3773 | 0.080 |
Why?
|
| Eicosanoids | 1 | 2008 | 16 | 0.080 |
Why?
|
| Lipoxygenase Inhibitors | 1 | 2008 | 34 | 0.080 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 1 | 2008 | 33 | 0.080 |
Why?
|
| Aging | 1 | 1993 | 727 | 0.070 |
Why?
|
| Cyclooxygenase 2 | 1 | 2008 | 99 | 0.070 |
Why?
|
| Vinblastine | 3 | 2002 | 100 | 0.070 |
Why?
|
| Chromosomes, Human, Pair 7 | 1 | 2007 | 79 | 0.070 |
Why?
|
| Pyrazoles | 1 | 2008 | 150 | 0.070 |
Why?
|
| Bone Marrow Cells | 7 | 1976 | 262 | 0.070 |
Why?
|
| Glutamates | 1 | 2007 | 88 | 0.070 |
Why?
|
| Infant | 13 | 1998 | 3191 | 0.070 |
Why?
|
| Cytarabine | 6 | 1982 | 219 | 0.070 |
Why?
|
| Asparaginase | 4 | 1982 | 35 | 0.070 |
Why?
|
| Guanine | 1 | 2007 | 207 | 0.060 |
Why?
|
| United States | 3 | 2008 | 7108 | 0.060 |
Why?
|
| Dacarbazine | 1 | 2006 | 101 | 0.060 |
Why?
|
| Tegafur | 1 | 2005 | 17 | 0.060 |
Why?
|
| Drug Therapy, Combination | 8 | 1982 | 785 | 0.060 |
Why?
|
| Uracil | 1 | 2005 | 55 | 0.060 |
Why?
|
| Carbazoles | 1 | 2004 | 33 | 0.060 |
Why?
|
| Neuroblastoma | 3 | 1977 | 400 | 0.060 |
Why?
|
| Dipeptides | 1 | 2004 | 42 | 0.060 |
Why?
|
| Prodrugs | 1 | 2004 | 51 | 0.060 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2019 | 476 | 0.050 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2004 | 160 | 0.050 |
Why?
|
| Confidence Intervals | 1 | 2003 | 221 | 0.050 |
Why?
|
| Biomarkers, Tumor | 2 | 2008 | 1545 | 0.050 |
Why?
|
| Leukemia, Myeloid, Acute | 5 | 1976 | 799 | 0.050 |
Why?
|
| Age Factors | 3 | 2019 | 1880 | 0.050 |
Why?
|
| Severity of Illness Index | 1 | 2008 | 1862 | 0.050 |
Why?
|
| Oligonucleotides, Antisense | 1 | 2002 | 67 | 0.050 |
Why?
|
| Thionucleotides | 1 | 2002 | 55 | 0.050 |
Why?
|
| Anaphylaxis | 1 | 1982 | 33 | 0.050 |
Why?
|
| Insurance, Liability | 1 | 1981 | 10 | 0.050 |
Why?
|
| Radiotherapy Dosage | 3 | 2001 | 468 | 0.050 |
Why?
|
| ErbB Receptors | 3 | 2009 | 499 | 0.050 |
Why?
|
| Bone Marrow Examination | 5 | 1987 | 47 | 0.050 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 1 | 1981 | 48 | 0.040 |
Why?
|
| Research | 1 | 1981 | 251 | 0.040 |
Why?
|
| Surveys and Questionnaires | 1 | 2008 | 2655 | 0.040 |
Why?
|
| Cell Cycle | 2 | 1982 | 508 | 0.040 |
Why?
|
| Thymidine | 6 | 1982 | 59 | 0.040 |
Why?
|
| Tritium | 6 | 1982 | 133 | 0.040 |
Why?
|
| Ceftizoxime | 1 | 1999 | 3 | 0.040 |
Why?
|
| Anemia, Hemolytic, Autoimmune | 1 | 1999 | 14 | 0.040 |
Why?
|
| Cephalosporins | 1 | 1999 | 24 | 0.040 |
Why?
|
| Drug Combinations | 4 | 2005 | 203 | 0.040 |
Why?
|
| Administration, Oral | 3 | 2001 | 667 | 0.040 |
Why?
|
| Leukocyte Count | 2 | 1993 | 224 | 0.040 |
Why?
|
| Antiphospholipid Syndrome | 1 | 1999 | 21 | 0.040 |
Why?
|
| Plasma Exchange | 1 | 1999 | 30 | 0.040 |
Why?
|
| American Cancer Society | 1 | 1998 | 13 | 0.040 |
Why?
|
| Vincristine | 6 | 1982 | 111 | 0.040 |
Why?
|
| Karyotyping | 2 | 1993 | 253 | 0.040 |
Why?
|
| Esophagitis | 1 | 1998 | 43 | 0.040 |
Why?
|
| Kinetics | 5 | 1982 | 1534 | 0.040 |
Why?
|
| Blood Platelets | 2 | 2016 | 150 | 0.040 |
Why?
|
| Glycoproteins | 1 | 1999 | 235 | 0.040 |
Why?
|
| Autoantibodies | 1 | 1999 | 270 | 0.040 |
Why?
|
| DNA Nucleotidyltransferases | 1 | 1977 | 32 | 0.040 |
Why?
|
| Adolescent | 11 | 1998 | 9342 | 0.040 |
Why?
|
| In Situ Hybridization, Fluorescence | 2 | 2008 | 352 | 0.030 |
Why?
|
| Platelet Glycoprotein GPIb-IX Complex | 1 | 2016 | 6 | 0.030 |
Why?
|
| Comprehensive Health Care | 1 | 1996 | 13 | 0.030 |
Why?
|
| NADPH Oxidase 2 | 1 | 2016 | 22 | 0.030 |
Why?
|
| Matrix Metalloproteinases | 1 | 2016 | 29 | 0.030 |
Why?
|
| Urokinase-Type Plasminogen Activator | 1 | 2016 | 51 | 0.030 |
Why?
|
| Autoimmune Diseases | 1 | 1999 | 250 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 2016 | 79 | 0.030 |
Why?
|
| Receptors, CXCR4 | 1 | 2016 | 45 | 0.030 |
Why?
|
| Professional-Family Relations | 1 | 1996 | 54 | 0.030 |
Why?
|
| Hindlimb | 1 | 2016 | 96 | 0.030 |
Why?
|
| Clinical Protocols | 1 | 1996 | 158 | 0.030 |
Why?
|
| Remission Induction | 2 | 2008 | 741 | 0.030 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 1996 | 59 | 0.030 |
Why?
|
| Health Resources | 1 | 1996 | 80 | 0.030 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2016 | 182 | 0.030 |
Why?
|
| Critical Care | 1 | 1999 | 384 | 0.030 |
Why?
|
| Stress, Mechanical | 1 | 2016 | 253 | 0.030 |
Why?
|
| Arteries | 1 | 2016 | 179 | 0.030 |
Why?
|
| Aneuploidy | 2 | 2007 | 57 | 0.030 |
Why?
|
| Monocytes | 1 | 2016 | 221 | 0.030 |
Why?
|
| T-Lymphocytes | 2 | 2016 | 1221 | 0.030 |
Why?
|
| Bone Neoplasms | 3 | 1987 | 321 | 0.030 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 3 | 2001 | 166 | 0.030 |
Why?
|
| Area Under Curve | 2 | 2007 | 338 | 0.030 |
Why?
|
| Patient Care Team | 1 | 1996 | 284 | 0.030 |
Why?
|
| Time Factors | 5 | 2010 | 5359 | 0.030 |
Why?
|
| Logistic Models | 2 | 2008 | 1214 | 0.030 |
Why?
|
| Reactive Oxygen Species | 1 | 2016 | 490 | 0.030 |
Why?
|
| Premedication | 2 | 2003 | 57 | 0.030 |
Why?
|
| Leukopenia | 1 | 1993 | 66 | 0.030 |
Why?
|
| Autoradiography | 3 | 1982 | 69 | 0.030 |
Why?
|
| Health Services Accessibility | 1 | 1996 | 436 | 0.030 |
Why?
|
| Immunophenotyping | 1 | 1993 | 217 | 0.030 |
Why?
|
| Acute Disease | 3 | 1982 | 846 | 0.020 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2008 | 1284 | 0.020 |
Why?
|
| Physician-Patient Relations | 1 | 1996 | 625 | 0.020 |
Why?
|
| Blood Transfusion | 3 | 1984 | 171 | 0.020 |
Why?
|
| DNA, Neoplasm | 1 | 1971 | 266 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2016 | 1669 | 0.020 |
Why?
|
| Hematopoiesis | 1 | 1970 | 168 | 0.020 |
Why?
|
| Chloramphenicol | 1 | 1969 | 18 | 0.020 |
Why?
|
| Risk | 3 | 1981 | 657 | 0.020 |
Why?
|
| Prednisone | 3 | 1982 | 255 | 0.020 |
Why?
|
| Anemia, Aplastic | 1 | 1969 | 32 | 0.020 |
Why?
|
| Diseases in Twins | 1 | 1969 | 65 | 0.020 |
Why?
|
| Cohort Studies | 2 | 2007 | 2887 | 0.020 |
Why?
|
| Cetuximab | 1 | 2009 | 115 | 0.020 |
Why?
|
| Histocytochemistry | 2 | 1987 | 130 | 0.020 |
Why?
|
| Erlotinib Hydrochloride | 1 | 2008 | 88 | 0.020 |
Why?
|
| Gene Amplification | 1 | 2008 | 135 | 0.020 |
Why?
|
| Celecoxib | 1 | 2008 | 31 | 0.020 |
Why?
|
| Purpura, Thrombocytopenic | 1 | 1967 | 6 | 0.020 |
Why?
|
| Wiskott-Aldrich Syndrome | 1 | 1967 | 2 | 0.020 |
Why?
|
| Chemoradiotherapy | 1 | 2010 | 306 | 0.020 |
Why?
|
| Microscopy, Electron | 2 | 1987 | 511 | 0.020 |
Why?
|
| DNA | 4 | 1982 | 1311 | 0.020 |
Why?
|
| Gene Expression Regulation | 1 | 2016 | 1983 | 0.020 |
Why?
|
| Rhabdomyosarcoma | 2 | 1978 | 42 | 0.020 |
Why?
|
| Centrifugation, Density Gradient | 1 | 1987 | 112 | 0.020 |
Why?
|
| Recurrence | 3 | 1999 | 1145 | 0.020 |
Why?
|
| Receptors, Estrogen | 1 | 2009 | 394 | 0.020 |
Why?
|
| Splenectomy | 2 | 1982 | 82 | 0.020 |
Why?
|
| Pemetrexed | 1 | 2007 | 76 | 0.020 |
Why?
|
| Blood Cell Count | 2 | 2001 | 79 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2009 | 855 | 0.020 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2008 | 217 | 0.020 |
Why?
|
| Bone Marrow Transplantation | 1 | 1987 | 283 | 0.020 |
Why?
|
| Hydrocortisone | 3 | 1973 | 301 | 0.020 |
Why?
|
| Thrombocytopenia | 1 | 1967 | 187 | 0.020 |
Why?
|
| Transforming Growth Factor alpha | 1 | 2005 | 50 | 0.020 |
Why?
|
| Nervous System Neoplasms | 1 | 1985 | 11 | 0.020 |
Why?
|
| DNA Mutational Analysis | 1 | 2007 | 529 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2008 | 983 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2008 | 726 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 1 | 2007 | 919 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2007 | 848 | 0.010 |
Why?
|
| Pleural Effusion | 1 | 2004 | 47 | 0.010 |
Why?
|
| Drug Hypersensitivity | 1 | 2004 | 37 | 0.010 |
Why?
|
| Isoflurophate | 1 | 1964 | 3 | 0.010 |
Why?
|
| Phosphorus Isotopes | 1 | 1964 | 24 | 0.010 |
Why?
|
| Salvage Therapy | 1 | 2005 | 230 | 0.010 |
Why?
|
| Remission, Spontaneous | 3 | 1979 | 52 | 0.010 |
Why?
|
| Hypotension | 1 | 2004 | 71 | 0.010 |
Why?
|
| Sulfamethoxazole | 1 | 1984 | 2 | 0.010 |
Why?
|
| Environment, Controlled | 1 | 1984 | 8 | 0.010 |
Why?
|
| Trimethoprim, Sulfamethoxazole Drug Combination | 1 | 1984 | 18 | 0.010 |
Why?
|
| Patient Isolation | 1 | 1984 | 14 | 0.010 |
Why?
|
| Granulocytes | 1 | 1984 | 38 | 0.010 |
Why?
|
| Trimethoprim | 1 | 1984 | 15 | 0.010 |
Why?
|
| Quality of Life | 2 | 2005 | 1682 | 0.010 |
Why?
|
| Genetics, Medical | 1 | 1964 | 52 | 0.010 |
Why?
|
| Probability | 2 | 1982 | 351 | 0.010 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2005 | 405 | 0.010 |
Why?
|
| Isoantibodies | 2 | 1999 | 120 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2008 | 1801 | 0.010 |
Why?
|
| Neutropenia | 1 | 1964 | 214 | 0.010 |
Why?
|
| Biopsy | 1 | 1987 | 1184 | 0.010 |
Why?
|
| Bryostatins | 1 | 2003 | 14 | 0.010 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2009 | 952 | 0.010 |
Why?
|
| Lactones | 1 | 2003 | 26 | 0.010 |
Why?
|
| Macrolides | 1 | 2003 | 30 | 0.010 |
Why?
|
| Survival | 1 | 2002 | 21 | 0.010 |
Why?
|
| Antibodies, Monoclonal | 1 | 2009 | 1396 | 0.010 |
Why?
|
| Erwinia | 1 | 1982 | 2 | 0.010 |
Why?
|
| Genes, bcl-2 | 1 | 2002 | 15 | 0.010 |
Why?
|
| Mice | 1 | 2016 | 11851 | 0.010 |
Why?
|
| Exchange Transfusion, Whole Blood | 2 | 1972 | 18 | 0.010 |
Why?
|
| Bacterial Infections | 1 | 1984 | 184 | 0.010 |
Why?
|
| Drug Evaluation | 1 | 2001 | 137 | 0.010 |
Why?
|
| United States Dept. of Health and Human Services | 1 | 1981 | 5 | 0.010 |
Why?
|
| Liposomes | 1 | 2001 | 93 | 0.010 |
Why?
|
| Interleukin-6 | 1 | 2003 | 262 | 0.010 |
Why?
|
| Biopsy, Needle | 1 | 1982 | 231 | 0.010 |
Why?
|
| Safety | 1 | 2001 | 145 | 0.010 |
Why?
|
| Topoisomerase I Inhibitors | 1 | 2001 | 34 | 0.010 |
Why?
|
| Radiation Pneumonitis | 1 | 2001 | 21 | 0.010 |
Why?
|
| Flow Cytometry | 1 | 1982 | 690 | 0.010 |
Why?
|
| Glucocorticoids | 1 | 2003 | 357 | 0.010 |
Why?
|
| Lymphocytes | 1 | 1982 | 468 | 0.010 |
Why?
|
| Morals | 1 | 1981 | 94 | 0.010 |
Why?
|
| Creatinine | 1 | 2001 | 294 | 0.010 |
Why?
|
| Coombs Test | 1 | 1999 | 8 | 0.010 |
Why?
|
| North America | 1 | 2000 | 188 | 0.010 |
Why?
|
| Polyethylene Glycols | 1 | 2001 | 360 | 0.010 |
Why?
|
| Cell Membrane | 1 | 1982 | 677 | 0.010 |
Why?
|
| Hemolysis | 1 | 1999 | 64 | 0.010 |
Why?
|
| Feasibility Studies | 1 | 2001 | 785 | 0.010 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2003 | 700 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2008 | 4331 | 0.010 |
Why?
|
| Antigen-Antibody Complex | 1 | 1999 | 87 | 0.010 |
Why?
|
| beta 2-Glycoprotein I | 1 | 1999 | 6 | 0.010 |
Why?
|
| Gangrene | 1 | 1999 | 7 | 0.010 |
Why?
|
| Europe | 1 | 2000 | 324 | 0.010 |
Why?
|
| Scleroderma, Localized | 1 | 1999 | 9 | 0.010 |
Why?
|
| Escherichia coli | 1 | 1982 | 607 | 0.010 |
Why?
|
| Hematoma, Subdural | 1 | 1999 | 25 | 0.010 |
Why?
|
| Ethics, Medical | 1 | 1981 | 306 | 0.010 |
Why?
|
| Filgrastim | 1 | 1998 | 57 | 0.010 |
Why?
|
| Leg | 1 | 1999 | 140 | 0.010 |
Why?
|
| Fingers | 1 | 1999 | 69 | 0.010 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2002 | 605 | 0.010 |
Why?
|
| Anti-Bacterial Agents | 1 | 1984 | 798 | 0.010 |
Why?
|
| Fatal Outcome | 1 | 1999 | 296 | 0.010 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 1998 | 135 | 0.010 |
Why?
|
| Wilms Tumor | 1 | 1977 | 38 | 0.010 |
Why?
|
| Antibodies | 1 | 1999 | 353 | 0.010 |
Why?
|
| Thorax | 1 | 1997 | 77 | 0.010 |
Why?
|
| Oligonucleotides | 1 | 1977 | 92 | 0.010 |
Why?
|
| Ischemia | 1 | 1999 | 253 | 0.010 |
Why?
|
| Animals | 1 | 2016 | 27528 | 0.010 |
Why?
|
| Radiation Dosage | 1 | 1997 | 230 | 0.010 |
Why?
|
| Osteosarcoma | 1 | 1977 | 161 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 1998 | 1008 | 0.010 |
Why?
|
| Thrombosis | 1 | 1999 | 302 | 0.010 |
Why?
|
| Phenotype | 1 | 1982 | 2458 | 0.010 |
Why?
|
| Anticoagulants | 1 | 1999 | 432 | 0.010 |
Why?
|
| Nephrectomy | 1 | 1977 | 291 | 0.010 |
Why?
|
| Body Surface Area | 1 | 1995 | 36 | 0.010 |
Why?
|
| Infant, Newborn | 2 | 1998 | 2499 | 0.010 |
Why?
|
| Phagocytosis | 2 | 1974 | 86 | 0.010 |
Why?
|
| Phagocyte Bactericidal Dysfunction | 1 | 1974 | 2 | 0.010 |
Why?
|
| Pediatrics | 1 | 1998 | 360 | 0.010 |
Why?
|
| Drug Antagonism | 1 | 1973 | 8 | 0.010 |
Why?
|
| Research Design | 1 | 1997 | 591 | 0.010 |
Why?
|
| Immunosuppressive Agents | 1 | 1999 | 979 | 0.010 |
Why?
|
| Bone Marrow Diseases | 2 | 1985 | 40 | 0.010 |
Why?
|
| Hodgkin Disease | 1 | 1973 | 181 | 0.010 |
Why?
|
| Methylprednisolone | 1 | 1972 | 64 | 0.010 |
Why?
|
| Deoxyuridine | 1 | 1971 | 3 | 0.010 |
Why?
|
| Depression, Chemical | 1 | 1971 | 27 | 0.010 |
Why?
|
| Culture Techniques | 1 | 1971 | 91 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 1998 | 3680 | 0.010 |
Why?
|
| Injections, Spinal | 2 | 1982 | 45 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2003 | 3475 | 0.010 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 1971 | 261 | 0.010 |
Why?
|
| gamma-Globulins | 1 | 1967 | 16 | 0.000 |
Why?
|
| Circadian Rhythm | 1 | 1970 | 303 | 0.000 |
Why?
|
| Blood Group Antigens | 1 | 1967 | 17 | 0.000 |
Why?
|
| Medulloblastoma | 1 | 1967 | 37 | 0.000 |
Why?
|
| Spinal Cord Neoplasms | 1 | 1967 | 48 | 0.000 |
Why?
|
| Cells, Cultured | 1 | 1972 | 2887 | 0.000 |
Why?
|
| Pedigree | 1 | 1967 | 971 | 0.000 |
Why?
|
| Pharmacogenetics | 1 | 1969 | 437 | 0.000 |
Why?
|
| Inflammation | 1 | 1970 | 981 | 0.000 |
Why?
|
| Cell Differentiation | 1 | 1970 | 1533 | 0.000 |
Why?
|
| Mercaptopurine | 1 | 1982 | 53 | 0.000 |
Why?
|
| Meningeal Neoplasms | 1 | 1979 | 66 | 0.000 |
Why?
|
| Neoplasms, Unknown Primary | 1 | 1978 | 15 | 0.000 |
Why?
|
| Orbital Neoplasms | 1 | 1978 | 17 | 0.000 |
Why?
|
| Central Nervous System | 1 | 1979 | 153 | 0.000 |
Why?
|
| Facial Neoplasms | 1 | 1978 | 25 | 0.000 |
Why?
|
| Ear Neoplasms | 1 | 1978 | 13 | 0.000 |
Why?
|
| Ear, Middle | 1 | 1978 | 26 | 0.000 |
Why?
|
| Testicular Neoplasms | 1 | 1979 | 113 | 0.000 |
Why?
|
| Nasopharyngeal Neoplasms | 1 | 1978 | 47 | 0.000 |
Why?
|
| Infusions, Parenteral | 1 | 1976 | 51 | 0.000 |
Why?
|
| Daunorubicin | 1 | 1976 | 78 | 0.000 |
Why?
|
| Sex Factors | 1 | 1979 | 1075 | 0.000 |
Why?
|
| Blood Bactericidal Activity | 1 | 1974 | 5 | 0.000 |
Why?
|
| Staphylococcus | 1 | 1974 | 24 | 0.000 |
Why?
|
| Candida albicans | 1 | 1974 | 32 | 0.000 |
Why?
|
| Alkaline Phosphatase | 1 | 1974 | 132 | 0.000 |
Why?
|
| Chemotaxis | 1 | 1974 | 73 | 0.000 |
Why?
|
| Cytoplasmic Granules | 1 | 1974 | 96 | 0.000 |
Why?
|
| Staining and Labeling | 1 | 1974 | 169 | 0.000 |
Why?
|
| Lysosomes | 1 | 1974 | 113 | 0.000 |
Why?
|
| Cytoplasm | 1 | 1974 | 285 | 0.000 |
Why?
|
| Leukocytes | 1 | 1974 | 209 | 0.000 |
Why?
|
| In Vitro Techniques | 1 | 1974 | 996 | 0.000 |
Why?
|
| Cell Nucleus | 1 | 1974 | 602 | 0.000 |
Why?
|